Table 1.
Baseline Characteristics Stratified by ALBI Grade
| Parameter | ALBI Grade 1 (n=59) | ALBI Grade 2/3 (n=27) | P value |
|---|---|---|---|
| Age (y)* | 52.0±9.7 | 54.8±12.9 | 0.261 |
| Gender | 0.441 | ||
| Male | 48 (81.4) | 20 (74.1) | |
| Female | 11 (18.6) | 7 (25.9) | |
| ECOG | 0.826 | ||
| 0 | 45 (76.7) | 20 (74.1) | |
| 1 | 14 (23.3) | 7 (25.9) | |
| Hepatitis B surface antigen | 0.878 | ||
| Positive | 45 (76.7) | 21(77.8) | |
| Negative | 14 (23.3) | 6(22.2) | |
| Tumor size (cm) | 0.238 | ||
| ≤7 | 50 (84.7) | 20 (74.1) | |
| >7 | 9 (15.3) | 7 (25.9) | |
| Tumor number | 0.772 | ||
| Single | 26 (44.1) | 11 (40.7) | |
| Multiple | 33 (55.9) | 16 (59.3) | |
| BCLC grade | 0.769 | ||
| A | 25 (42.4) | 10 (37.0) | |
| B | 28 (47.4) | 15 (55.6) | |
| C | 6 (10.2) | 2 (7.4) | |
| CTP grade | 0.004 | ||
| A | 58 (98.7) | 22 (81.5) | |
| B | 1 (1.3) | 5 (18.5) | |
| α-fetoprotein level (ng/mL) † | 1260.7 (2.0–12,536.9) | 1620.2 (1.4–21,263.9) | 0.668 |
| Albumin level (μmol/L) † | 42.2 (12.6–47.8) | 37.1 (13.9–54.1) | <0.001 |
| Total bilirubin level (μmol/L) † | 13.6 (4.3–44.9) | 34.5 (5.1–51.6) | 0.016 |
| ALT level (U/L) † | 34.0 (7.2–77.4) | 59.1 (8.9–234.6) | <0.001 |
| AST level (U/L) † | 32.4 (14.7–221.3) | 59.9 (14.2–387.0) | <0.001 |
| INR* | 1.1±0.2(0.87–1.38) | 1.1±0.1(0.89–1.49) | 0.522 |
| Platelet count (109) † | 178.3 (55–569) | 169.5 (50–238) | 0.489 |
| TACE session | 0.112 | ||
| ≤3 | 43(72.9) | 15(55.6) | |
| >3 | 16(27.1) | 12(44.4) | |
| CRA session | 0.134 | ||
| ≤3 | 53(89.8) | 21(77.8) | |
| >3 | 6(10.2) | 6(22.2) | |
| TACE-related CR | 0.615 | ||
| Yes | 4(6.8) | 2(7.4) | |
| No | 55(93.2) | 25(92.6) |
Notes: Unless otherwise indicated data are number of patients, with percentage in parentheses. *Data are means ± standard deviation. †Data are medians, with interquartile range in parentheses.
Abbreviations: ALBI, albumin-bilirubin; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase; ALT, alanine aminotransferase; cm, centimeter; INR, international normalized ratio; BCLC, Barcelona Clinic Liver Cancer; CTP, Child-Turcotte-Pugh; TACE, transarterial chemoembolization; CRA, cryoablation; CR, complete response.